(R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide | 1132656-73-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
• 英文别名: (2R)-3-(4-Cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
• CAS: 1132656-73-5
• 化学式: C₁₉H₁₄F₃N₃O₃
• 分子量: 389.334
• InChiKey: JNGVJMBLXIUVRD-GOSISDBHSA-N

物化性质

• 熔点：
  78-80°C (dec.)
• 沸点：
  632.3±55.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-氨基-2-三氟甲基苯甲腈 在 氯化亚砜 、 potassium carbonate 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 6.33h， 生成 (R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  参考文献：
  名称：

  METHODS OF PRESCREENING AND TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS

  摘要：

  This invention relates to methods of prescreening and treatment of a breast cancer in a subject, and the subject can be either a male or female subject, including methods of prescreening then treating: metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed treatments with selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), fulvestrant, cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio), trilaciclib, lerociclib), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), mTOR inhibitor (everolimus), poly ADP ribose polymerase (PARP) inhibitor (olaparib (Lynparza) or talazoparib (Talzenna)), human epidermal growth factor receptor 2 (HER2) kinase inhibitor (lapatinib, neratinib (Nerlynx), dacomitinib (Vizimpro), or tucatinib (Tukysa)), HER2 antibody (trastuzumab (Herceptin), pertuzumab (Perjeta), margetuximab-cmkb (Margenza)), HER2 antibody drug conjugate (HER2 ADC) (am-trastuzumab-deruxtecan-nxki (Enhertu), ado-trastuzumab emtansine (Kadcyla), or pertuzumab/trastuzumab/hyaluronidase-zzxf (Phesgo)), atezolizumab (Tecentriq) (PD-L1 blocking antibody), pembrolizumab (Keytruda) (PD-L1 blocking antibody), sacituzumab govitecan (Trodelvy) (antibody drug conjugate for TNBC), bevacizumab (Avastin), and/or sabizabulin or a pharmaceutically acceptable salt thereof; metastasis in a subject suffering from breast cancer; HER2-positive; and/or ER mutant expressing breast cancer, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound as described herein.

  公开号：

  US20220257552A1

文献信息

• [EN] SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS<br/>[FR] FORMES SOLIDES DE MODULATEURS DE RÉCEPTEUR D'ANDROGÈNE
  申请人：UNIV TENNESSEE RES FOUNDATION

  公开号：WO2009036206A1

  公开（公告）日：2009-03-19

  The present invention relates to solid forms of (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)- 3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.

  本发明涉及(S)-N-(4-氰基-3-(三氟甲基)苯基)-3-(4-氰基苯氧基)-2-羟基-2-甲基丙酰胺的固体形式以及其生产方法。
• 一种合成光学活性α-羟基丙酰胺衍生物的方法
  申请人：石家庄市度智医药科技有限公司

  公开号：CN109761778A

  公开（公告）日：2019-05-17

  本发明公开了一种合成光学活性α‑羟基丙酰胺衍生物的方法，属于有机合成领域。通过以脯氨酸为手性助剂，与甲基丙烯酰氯经酰化、溴化、脱手性助剂、与4‑氰基‑3‑三氟甲基苯胺发生亲核取代反应，得3‑溴‑2‑羟基‑2‑甲基‑N‑[(4‑氰基‑3‑三氟甲基)苯基]丙酰胺。再与对氰基苯酚发生亲核取代反应，制得光学活性化合物3‑(4‑氰基苯氧基)‑N‑[4‑氰基‑3‑三氟甲基苯基]‑2‑羟基‑2‑甲基丙酰胺。利用光学活性的3‑溴‑2‑羟基‑2‑甲基丙酸与4‑硝基‑3‑三氟甲基苯胺发生氨解、与对乙酰胺基苯酚发生亲核取代反应，制得光学活性化合物3‑(4‑乙酰氧基苯氧基)‑N‑[4‑硝基‑3‑三氟甲基苯基]‑2‑羟基‑2‑甲基丙酰胺。本发明是一种高效合成光学活性α‑羟基丙酰胺衍生物的方法。
• Selective androgen receptor modulators and method of use thereof
  申请人：Dalton T. James

  公开号：US20070123563A1

  公开（公告）日：2007-05-31

  This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

  这项发明提供了SARM化合物及其在治疗受试者中的各种疾病或情况中的用途，包括但不限于肌肉消耗性疾病和/或紊乱或骨相关疾病和/或紊乱。
• METHOD OF TREATING ESTROGEN RECEPTOR (ER) -POSITIVE BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARMS)
  申请人：GTx, Inc.

  公开号：US20140080905A1

  公开（公告）日：2014-03-20

  This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer; b) treating a subject suffering from metastatic breast cancer; c) treating a subject suffering from refractory breast cancer; d) treating a subject suffering from AR-positive breast cancer; e) treating a subject suffering from AR-positive refractory breast cancer; f) treating a subject suffering from AR-positive metastatic breast cancer; g) treating a subject suffering from AR-positive and ER-positive breast cancer; h) treating a subject suffering from triple negative breast cancer; i) treating a subject suffering from advanced breast cancer; j) treating a subject suffering from breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; k) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer; l) prolonging survival of a subject with breast cancer, and/or m) prolonging the progression-free survival of a subject with breast cancer; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound, comprising administering to the subject a therapeutically effective amount of a SARM compound of this invention.

  本发明涉及治疗雄激素受体阳性乳腺癌的方法，例如治疗女性患者。因此，本发明提供了以下方法：a）治疗患有乳腺癌的患者；b）治疗患有转移性乳腺癌的患者；c）治疗患有难治性乳腺癌的患者；d）治疗患有AR阳性乳腺癌的患者；e）治疗患有AR阳性难治性乳腺癌的患者；f）治疗患有AR阳性转移性乳腺癌的患者；g）治疗患有AR阳性和ER阳性乳腺癌的患者；h）治疗患有三阴性乳腺癌的患者；i）治疗患有晚期乳腺癌的患者；j）治疗经SERM（他莫昔芬，托瑞米芬），芳香化酶抑制剂，曲妥珠单抗（赫赛汀，阿多曲妥珠单抗乳腺癌注射液），珀妥珠单抗（珀妥泽），拉帕替尼，依西美坦（阿罗马星），贝伐珠单抗（阿瓦斯汀）和/或富马酸雌二醇失败的患有乳腺癌的患者；k）治疗、预防、抑制或阻止患有乳腺癌的患者的转移；l）延长患有乳腺癌患者的生存期；和/或m）延长患有乳腺癌患者的无进展生存期；包括向患者施用本发明的选择性雄激素受体调节剂（SARM）化合物的治疗有效量。
• Selective androgen receptor modulators for treating muscle wasting
  申请人：Dalton T. James

  公开号：US20070161608A1

  公开（公告）日：2007-07-12

  This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.

  该发明提供了选择性雄激素受体调节剂(SARM)化合物及其在治疗受试者中的各种疾病和病症中的应用，包括但不限于肌肉消耗性疾病和/或紊乱或骨相关疾病和/或紊乱。